Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Comparative Effectiveness of Behavioral Interventions, Safety Devices, and Financial Incentives to Reduce Cellphone Use While Driving Among UBI Auto Policy Holders

Comparative Effectiveness of Behavioral Interventions, Safety Devices, and Financial Incentives to Reduce Cellphone Use While Driving Among UBI Auto Policy Holders

18 years - 99 years
All genders
The purpose of this study is to test different behavioral strategies to see if they are effective at reducing cell phone use while driving among Progressive Usage-Based Insurance (UBI) Snapshot policy holders. Snapshot monitors driving habits and allows Progressive to provide insurance rates based on them. The present study uses …
Learn More
Study comparing the effect of crizanlizumab plus standard of care to standard of care alone on renal function in sickle cell disease patients,with chronic kidney disease due to sickle cell nephropathy (STEADFAST).

Study comparing the effect of crizanlizumab plus standard of care to standard of care alone on renal function in sickle cell disease patients,with chronic kidney disease due to sickle cell nephropathy (STEADFAST).

16 years - 99 years
All genders
Phase 2
The main purpose of the study is to explore the effect of crizanlizumab on kidney function in people with long-term kidney disease caused by SCD. Kidney function of patients who receive crizanlizumab in addition to any regularly prescribed medications will be compared to that of patients who receive their regularly …
Learn More
Study Evaluating Participants who Received CanGaroo Envelope Tyrx Envelope or No Envelope During CIED Implantation

Study Evaluating Participants who Received CanGaroo Envelope Tyrx Envelope or No Envelope During CIED Implantation

18 years - 99 years
All genders
People who have had surgery to implant a medical device that helps their heart may have had their surgery done in slightly different ways. In this study, the investigators are looking for people to participate who need to undergo another surgical procedure to change or revise their implanted heart device. …
Learn More
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
Learn More
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

18 years - 99 years
All genders
Phase 2
Interventional
The overall objectives of the study is to establish visual image interpretation criteria for 18F-fluciclovine PET in detecting recurrent brain metastases and to establish other image interpretation criteria for 18F-fluciclovine PET in detecting recurrent brain metastases.
Learn More
Disrupt CAD III With the Shockwave Coronary IVL System

Disrupt CAD III With the Shockwave Coronary IVL System

18 years - 99 years
All genders
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries prior to stenting. Disrupt CAD III is being conducted as a staged pivotal study.
Learn More
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

18 years - 99 years
All genders
This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM. Subjects should have received 3 Cycles of standard induction therapy prior to undergoing leukapheresis procedure to collect autologous …
Learn More
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD ( Graft vs Host)

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD ( Graft vs Host)

12 years - 99 years
All genders
Phase 1
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).
Learn More
Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects

Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects

18 years - 49 years
All genders
Phase 1
This is a study of AR-501 (gallium citrate) solution, administered via inhalation, in adults with P. aeruginosa infected cystic fibrosis (CF). The study will evaluate the safety and pharmacokinetic (PK) and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF.
Learn More
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

18 years - 99 years
All genders
Phase 2
Interventional
This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
Learn More
481 - 490 of 1243